NYSE American - Delayed Quote USD

Regentis Biomaterials Ltd. (RGNT)

1.1900 +0.0200 (+1.71%)

At close: November 6 at 4:00:00 PM EST

1.1200 -0.0700 (-5.88%)

After hours: November 6 at 4:34:32 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal

ACCESS Newswire 26d ago

RGNT
-4.27%
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City

ACCESS Newswire 29d ago

RGNT
-4.27%
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.

GlobeNewswire 1mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

NewMediaWire 1mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

NewMediaWire 2mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

NewMediaWire 2mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

NewMediaWire 3mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market

NewMediaWire 3mo ago

RGNT
-4.27%
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

ACCESS Newswire 3mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process

NewMediaWire 3mo ago

RGNT
-4.27%
Why Did RGNT Stock Surge More Than 850% Today?

Stocktwits 4mo ago

RGNT
-4.27%
Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC

NewMediaWire 4mo ago

RGNT
-4.27%

Performance Overview

Return	RGNT	S&P 500 (^GSPC)
YTD	-82.34%	+7.76%
1-Year	-83.92%	+9.77%
3-Year	-83.92%	+68.96%

U.S. markets closed

Regentis Biomaterials Ltd. (RGNT)

Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal

Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.

Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market

Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process

Why Did RGNT Stock Surge More Than 850% Today?

Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC